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An expert meeting was organized by the World Health Organization (WHO) and held in
Stockholm on 15-18 June 1997. The objective ofthis meeting was to derive consensus toxic
equivalency factors (TEFs) for polchlorinated dibenzo-p-dioxins (PCDDs) and dibenzofirans
(PCDFs) and dioinlike polhiorinated biphenyls (PCBs) for both human, fish, and wildlife
risk assessment. Based on existing literature data, TEFs were (re)evaluated and either revised
(mammals) or established (fish and birds). A few mammalian WHO-TEFs were revised, indud-
ing 1,2,3,7,8-pentachiornated DD, octachiorinated DD, octachlorinated DF, and PCB 77.
These mammalian TEFs arealso considered applicable forhumans andwildmammalian species.
Furthermore, it was concuded that there was insufficient in vivoevidence to continue the use of
TEFs for some di-ortho PCBs, as suggested earlier by Ahlborg et al. [Chemosphere
28:1049-1067 (1994)1. In addition, TEFs for fish andbirds were determined. TheWHOwork-
ing group attempted to harmonize TEFs across different tana to the extent possible. However,
totalsynchronization ofTEFs was not feasible, as there were orders ofa mndedifference in
TEFs between tan for some compounds. In this respect, the absent or very low response of fish
to mono-ortho PCBs isnmost noticeable compared to mamas and birds. Uncerta iies that
could compromise the TEF concept were albo reviewed, interactions, dif-
ferences in shape of thedose-response curve, andspecies responsiveness. Inspite ofthese uncer-
tainties, it was concluded that the TEF concept is still the mostplausible and feasible approach
for risk assessment ofhalogenated aromatic hydrocarbons with dio properties. Key work
dioxins, humans, PCBs, polychlorinated biphenyls, TEFs, toxic equivalency, uncertainties,
wildlife. EnvironHealthPerspcat106:775-792 (1998). [Online 10 November 1998]
http:.I/ehpnnt.niebs.nihgovdocs/I9998/106p775-792vandinbcg/abstraithml
Polychlorinated dibenzo-p-dioxins (PCDDs),
dibenzofurans (PCDFs), and biphenyls
(PCBs) constitute a group ofpersistent envi-
ronmental chemicals. Due to theirhydropho-
bic nature and resistance towards metabo-
lism, these chemicals have been found in fatty
tissues of animals and humans. Several
PCDDs, PCDFs, and PCBs have been
shown to cause toxic responses similar to
those caused by2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), the most potent congener
within these groups of compounds. These
toxic responses include dermal toxicity,
immunotoxicity, carcinogenicity, and
adverse effects on reproduction, develop-
ment, and endocrine functions.
PCDDs, PCDFs, and PCBs exist in
environmental and biological samples as
complex mixtures of various congeners
whose relative concentrations differ across
trophic levels. These differences are caused
by environmental degradation, which refers
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to the different environmental fates of con-
geners with different solubilities, volatilities,
and rates of degradation/metabolism. As a
result, these mixtures change spatially and
temporally into the environment and are
very different from the technical mixtures
originally released into the environment.
The complex nature of PCDD, PCDF,
and PCB mixtures complicates the risk
evaluation for humans, fish, and wildlife.
For this purpose, the concept of toxic
equivalency factors (TEFs) has been devel-
oped and introduced to facilitate risk assess-
ment and regulatory control ofexposure to
these mixtures. To apply this TEF concept,
a fundamental understanding ofthe mecha-
nism ofaction is a prerequisite. At present,
there is sufficient evidence available that
there is a common mechanism for these
compounds, involving binding to the aryl
hydrocarbon (Ah) receptor as an initial step.
When applying the TEF concept, the toxic-
ity of these compounds relative to that of
2,3,7,8-TCDD is determined on the basis
of available in vivo and in vitro data.
However, it should also be understood that
the TEF concept is based on a number of
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assumptions and has limitations. In this
respect, the most basic assumption is that the
combined effects ofthe different congeners
aredose orconcentration additive, and results
ofmanystudies supportthis assumption.
In the last decade, several different TEF
schemes have been developed for PCDDs,
PCDFs, and dioxinlike PCBs. Recognizing
the need for a harmonized approach in set-
ting internationally agreed upon TEFs, the
European Centre ofEnvironmental Health
ofthe World Health Organization (ECEH-
WHO) and the International Programme on
Chemical Safety (IPCS) have initiated a pro-
gram to derive TEFs for these compounds
for assessing the impact ofthese compounds
onhuman andenvironmental health.
At an initial WHO consultation on the
derivation ofTEFs for wildlife for dioxin-
like compounds, held on 9-10 August
1996 in Bilthoven, The Netherlands, the
question was addressed whether it is appro-
priate to use TEFs derived for the purpose
of human risk assessment to estimate the
risk for fish and wildlife species. The meet-
ing concluded that there was a need to
derive separate sets of TEFs for fish and
wildlife, and recommended to combine
this effort with a reevaluation and possible
update of existing TEFs for human health
risk assessment. In addition, it was recom-
mended that the same TEFs for human
health and wildlife should be used as much
as possible.
For the (re)evaluation process, experi-
mental data on the relative potencies (REPs)
ofPCDDs, PCDFs, and dioxinlike PCBs for
mammalian, avian, andfishspecies have been
collected by the Institute ofEnvironmental
Medicine, Karolinska Institute, Stockholm,
Sweden, and inserted into a database.
Following collection ofall available informa-
tion, an ECEH-WHO/IPCS meeting was
held at the Karolinska Institute on 15-18
June 1997. The objective ofthe meeting was
to assess the REP values in the database and
to derive consensus TEFs for PCDDs,
PCDFs, and dioxinlike PCBs for both
human, fish, and wildlife risk assessment.
The results of this process are presented in
thispaper.
TEF Concept and Data
Requirements
Toxic Equivalency Factors, Relative
Potencies, andToxic Equivalents
In the literature, there is some confusion
regarding the definition of the term toxic
equivalency factor (TEF). One reason for
confusion is the fact that the term TEF has
been used in two different ways: 1) as a rela-
tive potency value that is based on the
results ofseveral in vivoand in vitrostudies;
or 2) as the relative potency ofa compound
relative to TCDD to cause a particular toxic
or biological effect in a single study.
Furthermore, TEF is frequently used to refer
to an end point that is not a toxic response
per se, such as binding affinity to the aryl
hydrocarbon (Ah) receptor or induction of
cytochrome P4501A1, although these bio-
chemical effects may in some way be associ-
atedwithsubsequent toxic responses.
It is important to realize that in this
paper and associated WHO publications
TEF indicates an order of magnitude esti-
mate ofthe toxicity ofa compound relative
to TCDD. This consensus TEF value has
been derived using careful scientific judg-
ment after considering all available scientif-
ic data. However, when the potency of a
compound relative to TCDD has been
obtained in a single in vivo or in vitro
study, itwill be referred to as a REP value.
TEF values, in combination with
chemical residue data, can be used to calcu-
late toxic equivalent (TEQ) concentrations
in various environmental samples, includ-
ing animal tissues, soil, sediment, and
water. TEQ concentrations in samples are
calculated using the following equation:
TEQ = lnl[PCDDi x TEFi] +Xn2[PCDFi
xTEFi]+ n3[PCBi XTEFl. (1)
TEFs andTEQs are used for riskcharac-
terization and management purposes, e.g.,
to help prioritize areas ofconcern for dean-
up. However, in relation to the use ofTEFs
for abiotic compartments, the biological
meaning of these values is obscure. This is
caused by the fact that the assumed biologi-
cal or toxicological effect is influenced by
many physicochemical factors before the
actual uptake of the compounds by the
organism takes place. Nevertheless, TEQ
values can be used as relative measures
between different abiotic samples, e.g., sedi-
ment and soil, to prioritize remedial actions.
In relation to the initial transport of these
compounds from the abiotic to biotic com-
partment, it was recognized that congener-
specific biota-sediment accumulation factors
(BSAFs) can be used to predict the concen-
trations in fish tissue, after which these can
beconverted toTEQs usingTEFs.
The TEFs presented in this paper apply
only to AhR-mediated responses, and this
concept assumes a model ofdose additivity.
In relation to this prerequisite, we decided
that for PCDDs, PCDFs, and some planar
PCBs there is sufficient evidence from both
in vivo and in vitro studies supporting the
dose or concentration-additivity model for
Ah receptor-mediated responses. In addi-
tion, it should be emphasized that the TEF
concept cannot be applied to effects that
are not Ah receptor-mediated, and it does
not consider modulating effects of com-
pounds that are notAh receptorligands.
TEF values were determined for the fol-
lowing classes ofvertebrates: mammals, fish,
and birds. TEFs that were determined for
mammalian species were also considered to
be applicable for human risk assessment
purposes. It was condudedthat, to date, not
enough information was available to deter-
mine REP values in amphibians and rep-
tiles, such that TEFs could not be proposed
for these classes ofvertebrates. At this time,
development ofTEFs for invertebrates is
not recommended because there is limited
evidence for ligand activation ofAhR or for
TCDD-liketoxicityin invertebrates.
The criteria for induding a compound
in a fish and wildlife TEF scheme are the
same criteria as those used for the deriva-
tion human TEFs (1). These are 1) a com-
pound must show a structural relationship
to the PCDDs and PCDFs; 2) a com-
pound must bind to the Ah receptor; 3) a
compound must elicit Ah receptor-mediat-
ed biochemical and toxic responses; and 4)
a compound must be persistent and accu-
mulate in the food chain.
Compilation ofthe Database
Since 1993, the data of all available mam-
malian, bird, andfish studies on relative tox-
icity ofdioxinlike compounds that meet the
criteria of inclusion in a TEF scheme (1)
have been collected, and this information
has been stored in a database at the
Karolinska Institute in Stockholm (Sweden).
These publications were analyzed and the
data to be included in the database were
selected usingthefollowingcriteria:
I.At least one PCDD, PCDF, or PCB con-
gener and a reference compound must be
induded in thestudy.
2.Either TCDD or PCB 126 must be
included as a reference compound in the
same experiment or studied with the
same experimental design by the same
authors in another experiment.
3.The relevant end point should be affected
by the congener studied as well as the ref-
erencecompound.
PCB 126 was used as reference in some
cases, with an assigned REP of 0.1 for
mammals and birds or 0.005 for fish, based
on a variety of in vivo studies covering vari-
ous end points. The use of PCB 77 and
PCB 169 as reference compounds was no
longer included in this evaluation due to
the limited comparative information avail-
able for these two compounds. Only diox-
in-specific end points were induded in the
database (see criteria 3).
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However, it is recognized that some end
points such as liver enlargement and tumor
promotion are affected byboth dioxinlike and
nondioxinlike halogenated aryl hydrocarbons
(HAHs; e.g., mono- or di-ortho PCBs). In
addition, several biologicalortoxiceffects have
been described for PCBs, for example, which
are probably not related to an Ah receptor-
mediated mechanism ofaction. Among oth-
ers, these effects include a decrease in
dopamine levels (2,3), alterations in retinoid
andthyroidhormonelevels (4,5), andbinding
to the estrogen receptor (6). These effects
show distinctly different structure-activity
relationships for PCBs than thoseobserved for
Ah receptor binding involving multiple ortho
chlorine substitution orhydroxylated metabo-
lites. Based on thefour criteria mentioned ear-
lier, these effects, how biologically relevant
they might be, are not covered in this TEF
concept. For these compounds and their asso-
ciated effects, a different approach for risk
assessment is needed, which might possibly
involve thedevelopmentofan alternativetoxic
equivalency concept.
Compounds included in the database
are the 2,3,7,8-substituted PCDDs and
PCDFs and those PCBs with established
dioxinlike activity, especially the non- and
mono-ortho PCBs. We agreed that there are
a large number of other halogenated com-
pounds that meet the criteria for inclusion
in the TEF concept and could contribute to
the total concentration ofTEQs in environ-
mental samples. These include any or all of
the following classes of polychlorinated
compounds: naphthalenes, diphenyl ethers,
diphenyl toluenes, phenoxy anisoles,
biphenyl anisoles, xanthenes, xanthones,
anthracenes, fluorenes, dihydroanthracenes,
biphenyl methanes, phenylxylylethanes,
dibenzothiophenes, quaterphenyls, quater-
phenyl ethers, and biphenylenes. In addi-
tion to the chlorinated compounds, bromi-
nated and chloro/bromo-substituted ana-
logues of PCDDs (PBDDs) and PCDFs
(PBDFs) have been found in the environ-
ment (7-10) and are known to induce
CYPlA1 activity in vivo and in vitro (11).
PBDDs and PBDFs have also been shown
to cause developmental toxicity, and REPs
have been determined in mammals and fish
(12-14). However, it was decided that, at
present, insufficient environmental and tox-
icological data are available to establish a
TEF value for anyofthe above compounds.
Calculation ofREPs
The following methods were used to derive
REPs from the available data:
* REPs were used as reported in each pub-
lication; if experimental data were also
reported, these were used to calculate the
REPs using one ofthe methods below.
* REPs were calculated by comparing
dose-response curves or by using linear
interpolation oflog-doses, comparing the
same effect level; ifnecessary, corrections
were made for different control levels.
* REPs were determined from ratios of
medium effective dose (ED50), median
lethal dose (LD50), and median effective
concentration (EC50) values, tumor pro-
motion indexes, dissociation constant (Kd)
values forAh receptor binding, or directly
estimated from thegraphs presented.
All the data were compiled into a spread-
sheet format using Quattro Pro (version
6.0) for Windows (Corel Corporation
Limited). The database used for the deriva-
tion of TEF values is available from The
European Centre for Environment and
Health, World Health Organization,
Bilthoven, The Netherlands.
Basis for the Review Process
TEFs for MammalianWildife
TheTEF values, which are mainlybased on
rodent studies, should be suitable for both
human risk assessment and for estimating
the riskfor species ofmammalian wildlife.
Based on two semichronic studies with
mink and TCDD and PCB 169, the REP
ofPCB 169 was evaluated. In the first study
with adult male mink, a 28-day oral LD50
value (single dose) of 4.2 pg TCDD/kg
bodyweight (bw) was reported (15,16), and
a 28-day dietary median lethal concentra-
tion (LC50) of 4.3 ppb was calculated for
female mink. In the second study, PCB 169
was given to mink via the diet (17).
Exposure of adult females to dietary con-
centrations of0.05 mg PCB 169/kg bw for
131 days resulted in 50% mortality.
Assuming a daily feed consumption of 150
g and a body weight of 1 kg, the total
intake of PCB 169 was about 1,000 pg/kg
bw. By using the LD50 values of 4.2 for
TCDD and 1,000 for PCB 169, a value of
0.0042 can be calculated as a first estimate
for the relative potency of PCB 169 in
mink. Based on these calculations, the pre-
vious assigned TEF value of 0.01 for PCB
169 for human risk assessment seems fairly
reasonable for mink and gives some support
to the use ofsimilarTEF values for humans
andwild mammals.
The TEF concept is further supported
in mink by comparison ofthe no observed
adverse effect level (NOAEL) derived from
a meta-analysis ofmink reproductive toxic-
ity data (18) with the NOAEL calculated
from a mink laboratory reproductive study
in which the diets were subject to complete
chemical characterization (151). These two
independent analyses ofthe TEF approach,
utilizing different effects data sets and the
same set of international TEFs (1,20) for
the assessment ofmink reproductive toxici-
ty, confirmed one another. Overall these
results suggest that the relative potencies of
the PCBs, PCDDs, and PCDFs toward
minkreproductive toxicity are not different
from those of the rodent models from
which most ofthe datawere derived.
One argument that might be considered
to refine future risk assessment of mam-
malian wildlife is the substance-specific bio-
transformation capacity of different mam-
malian species. Certain marine mammals
might have a higher capacity to metabolize
dioxins and dioxinlike congeners than cer-
tain terrestrial mammals, but due to their
position in the foodchain and strictly aquat-
ic diet, body burdens can still be high. Due
to these differences in metabolic CYPlAl
capacities, it has been suggested that terres-
trial mammals, when compared to highly
exposed marine mammals, may experience
agreater threat from dioxinlike compounds,
e.g., PCB 126, than mammalian top preda-
tors in the aquatic foodwebs (21-25).
Furthermore, pharmacokinetic differ-
ences will undoubtedly contribute to the
interspecies variabilityobservedwith different
congeners. At present, the mammalian TEF
scheme is based on administered dose.
Although it has been discussed whether
mammalian TEFs should be derived based
on target tissue concentrations, this is at pre-
sentconsidered notfeasibledueto thelimited
amountofscientificinformation available.
TEFs forAh Receptor-mediated
Toxicityfor Fish
Fish, induding all salmonids that have been
studied, express CYP4501Aactivity (26,27),
which is an Ah receptor-mediated process
and can be induced by many (halogenated)
aromatichydrocarbons (28-31). This mech-
anism indicates that fish should be sensitive
to the effects ofAh receptor-active com-
pounds; but compared to mammals, fish are
less responsive to mono-ortho PCBs. The
hepatic cytochrome P450-dependent
enzymes in fish are considered to be func-
tionally similar to those of mammals (32).
In those instances where adequate data are
available, it appears that fish enzymes are
influenced by some ofthe same factors that
affect these enzymes in mammals: species
(32), strain (33), size and/or age (34), devel-
opmental stage (35), sex (36), reproductive
state (37), nutrition (38), and exposure to
certain types oforganic xenobiotic inducers
as well as environmental conditions (39).
The inclusion of fish in the TEF con-
cept is justified by the common Ah recep-
tor-mediated mechanism of response; this
was confirmed by many toxicological and
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biochemical studies during the last decades. of dioxinlike PCBs, PCDDs, and PCDFs. In addition, it has been established that
Fish-specific REPs have been derived from Generally, the REPs derived from CYP1A REPs determined for mortality in rainbow
mortality in early life stages in rainbow trout induction either in vivoor in vitroarehigher trout sac fry following waterborne exposure
(40-4 and from in vivo CYPIA induction than those derived from early life stage mor- are nearly identical to those determined for
in adult rainbow trout (45) and in vitro in tality (48). Injection of trout eggs with the same end point after egg injection
rainbow trout liver (RTL-W1) (44-46) and TCDD has been shown to result in the same (40,42,49). Thus, the REPs based on sac fry
gonadal cell lines (47). These have been effects and LD 0 as with maternal transfer of mortalitywere notinfluencedbythe route of
developed for ecological risk assessments the chemical (41) and has confirmed the exposure. Zabel et al. (50) also showed that
involving fish exposed to complex mixtures application oftheTEF conceptin fish. the REP for PCB 126 in producing lake
Table 1.Toxic equivalencyfactors (TEFs)for human risk assessment and mammals
Congener Description Old TEF WHO TEF
Dioxins
1,2,3,7,8-PentaCDD
1,2,3,4,7,8-HexaCDD
1,2,3,6,7,8-HexaCDD
1,2,3,7,8,9-HexaCDD
1,2,3,4,6,7,8-HeptaCDD
OctaCDD
Furans
2,3,7,8-TetraCDF
1,2,3,7,8-PentaCDF
2,3,4,7,8-PentaCDF
1,2,3,4,7,8-HexaCDF
1,2,3,6,7,8-HexaCDF
1,2,3,7,8,9-HexaCDF
2,3,4,6,7,8-HexaCDF
1,2,3,4,6,7,8-HeptaCDF
1,2,3,4,7,8,9-HeptaCDF
OctaCDF
Non-ortho PCBs
3,3',4,4'-TetraCB (77)8
3,4,4',5-TetraCB (81)
3,3',4,4',5-PentaCB (126)
3,3',4,4',5,5'-HexaCB
(169)
Based on new in vivotumor promotion data and CYP1A1/A2 induction potencies from subchronic
studies(79-81); a value closerto 1.0 is recommended.
Limited in vivodata are available, butmore recentLD50values continue to supportthe currentvalue(82,83);
no revision is recommended.
No new in vivodata. Recent in vitrodata supportthe currentvalue (84); no revision is recommended.
No new in vivoinformation; no revision is recommended.
Two recentsemichronic studies indicatevalues between 0.02 and 0.03forvarious end points (85,86);
no revision is recommended.
A recalculation ofthe old data in which exposure versustissue concentrations were compared suggests
that a lowervalue is more appropriate (87).
Recentsemichronic studies generally support a value of0.1 (88,89); less emphasis was put on LD50values;
no revision is recommended.
Although newsemichronic data suggestthatmice are more responsive (81,90),the combined potency
values indicatethe currentvalue isadequatelyprotective; no revision is recommended.
MostREPs dealing with relevanttoxic end points [e.g., (79)1 supportthe continued use ofa value of0.5.
Due tothefactthatthis congener is a major contributortototalTEQs in biological samples, confirmation
of recentimmunotoxicity data indicating a highervalue is strongly recommended (91); at present,
no revision is recommended.
Additional in vivopotencyvalues on nonspecific biological end points(liver,thymus, bodyweight
alterations) are inthe range ofthe currentTEF(92); no revision is recommended.
No newinformation; no revision is recommended.
Very limited data (93) and no new in vitroand QSAR data thatsuggest a change in value iswarranted;
no revision is recommended.
Limited new in vitroand QSAR information indicate a change ofvalue is notwarranted (93); no revision
is recommended.
Recentvalues greaterthan 0.01 are under discussion due to possible impurity oftestcompound and the
factthat no reference (TCDD/PCB126)was included atthetime ofstudies(94). In addition,the same study
reports approximatelythe same responsewith 1,2,3,4,7,8,9-heptaCDF, whereasthis congeneris knownto
be less persistentin vivo(95). Confirmation ofREPs>0.01 isrequired; no revision is recommended.
Avery limited data setis available andthe same commentholds asfor 1,2,3,4,6,7,8-heptaCDF; no revision
is recommended.
New in vivoEROD induction potencyvalues(81) and an expected structural similaritywith octaCDD for
the in vivosituation support a change in analogywith octaCDD.
Recentsubchronic studieswith EROD induction and hepatic retinol decreases suggesta value around
or below0.0001 (96-98),which is lowerthan the previous value based on tumor promotion (99); however,
impurity and background contamination (e.g, PCB 126) is an identified problem withthis congener. A
change in valueto 0.0001 is recommended.
Based on Ah receptor binding, in vitroCYP1Ainduction, and QSAR calculations, a value similarto PCB 77
was suggested (100-102). Itshould be noted thatin vitroREPs possibly overestimate the potencyofthis
compound, as in analogywith PCB 77, itis likelyto be metabolized efficiently byhigherorganisms;
however,this congener is detectable in certain wildlife species and human samples. Avalue of0.0001
is recommended.
Multiple invivoend points insemichronic studieswith rats,includingCYP1A1/A2 induction,tumorpromotion,
and hepatic retinol decreases, supportthe currentvalue (89,103,104); no revision is recommended.
Recent in vivoEROD induction andthymic atrophyvalues supporta conservative value of0.01 forthis
congener. Confirmation of recent immunotoxicity data possibly indicating a higher REP is strongly
recommended (91,105); no revision is recommended.
0.5 1
0.1 0.1
0.1 0.1
0.1 0.1
0.01 0.01
0.001 0.0001
0.1 0.1
0.05 0.05
0.5 0.5
0.1 0.1
0.1
0.1
0.1
0.1
0.1 0.1
0.01 0.01
0.01 0.01
0.001 0.0001
0.0005 0.0001
- 0.0001
0.1 0.1
0.01 0.01
continued, nextpage
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trout early life stage mortality is similar to
the REP for the same response in rainbow
trout. These results are significant because
they suggest that TCDD-like congeners
show similar REPs in rainbow trout and lake
trout and support both the use of rainbow
trout REPs in assessments of risks to lake
trout and, perhaps, other fish species. While
this agreement in REPs for PCB 126
between trout species is encouraging, further
comparisons of REPs for other potent con-
geners and more disparate fish species are
needed. In relation to environmental risk
assessment, the use ofearly life stage mortali-
ty-specific TEFs and the egg toxicity equiva-
lent additivity model predicted that PCDDs,
PCDFs, and PCBs in Great Lakes lake trout
are currently below levels that cause early life
stage mortality (51). This information is in
agreement with recent observations ofjuve-
nile lake trout survival in this area of the
Great Lakes and gives further support for the
use ofthe TEF concept in fish.
One ofthe major differences between the
TEFs determined for mammals and fish is
the lack or low response to mono-ortho
PCBs in the latter taxa. Even with an
extremely sensitive Ah receptor-mediated
effect, the induction of CYPlAl, it was
found that fish arevery insensitive, ifsensitive
at all, to mono-ortho-substituted PCBs
(45,48,52-55). Similar lack of responses
toward mono-ortho PCBs have been observed
for early life stage mortality in rainbow trout
(40,42. Based on the above considerations,
we decided that fish should be included in
the TEF concept, but due to the deviations
found for PCBs, fish should be treated as a
separate taxa in this TEF evaluation.
TEFs for Birds
Although many studies with young or adult
birds have shown dioxinlike toxic and bio-
chemical effects ofTCDD and PCBs, these
studies were not designed for REPs ofcom-
pounds to be reliably derived (56-63). At
present, TEFs for birds can only be derived
from egg injection studies, studies with cul-
tured avian hepatocytes, and studies with
cultured thymus cells.
The end points mentioned above have
been studied in a number of avian species.
These species include domestic chicken,
duck, domestic goose, turkey, pheasant,
gull, common tern, double-crested cor-
morant, and American kestrel (64-68). As
with fish and mammals, Ah receptor-medi-
ated CYPlA1 induction has been found in
a large number of avian species, clearly
indicating an Ah receptor responsiveness in
this taxa. This justifies the inclusion of
birds in the TEF concept. The induction
ofCYPlA1 in avian systems has been stud-
ied for most of the environmentally rele-
vant PCDDs, PCDFs, and dioxinlike
PCBs. However, the number of studies
that could be used for this evaluation was
limited. REPs for Tier 1 studies were not
available for PCDDs and PCDFs, but for
some PCBs, Tier 1 studies (in ovo lethality)
were available. In general, REPs for
ethoxyresorufin-O-deethylase (EROD)
induction for dioxins, furans, and non-
ortho-PCBs in birds are in the same range
as those reported from mammalian sys-
tems. The major exception is TCDF,
which can be more potent than TCDD in
hepatocyte cultures from several species of
birds (65,66,69).
Based on studies with chicken embryos, it
has been concluded that birds can be highly
responsive toward non-ortho PCBs, although
much of the information available concerns
induction of CYPlAI and not distinct toxic
Table 1. (continued)
Congener Description Old TEF WHO TEF
Mono-ortho PCBs For this group of congeners, more than one mechanism of action (not only Ah receptor specific) is involved.
A variety of in vivo mammalian experiments have demonstrated distinct Ah receptor-mediated
biochemical and toxic effects. Among these are CYPlA1/lA2 induction and reproductive and teratogenic
effects similar to TCDD.
2,3,3',4,4'-PentaCB (105) The majority of potency values from subchronic bioassays support a value of less than 0.0002, including 0.0001 0.0001
those fortumor promotion and thymus atrophy (97,106). The immunotoxicity data suggest a TEF between
10-5 and 10O7 while acute in vivovalues for nonspecific end points, e.g., liver weight gain and body weight
decrease, are in the range of 10-3 and104; no revision is recommended.
2,3,4,4',5-PentaCB (114) There are no new data which suggest that the current value is not appropriate. OlderAh receptor 0.0005 0.0005
binding and enzyme induction data need confirmation regarding the present value (100,101,107); at
present no revision is recommended.
2,3',4,4',5-PentaCB (118) New data support the original value (91,96,108); no revision is recommended. 0.0001 0.0001
2',3,4,4',5-PentaCB (123) No new data are available; no revision is recommended. 0.0001 0.0001
2,3,3',4,4',5-HexaCB Recent data from semichronic studies suggestthatthe old value is appropriate (109). Higher REPs measuring 0.0005 0.0005
(156) nonspecific end points, e.g., effects on thyroid hormones and body and thymus weight, were not included
in the evaluation. Some concern was raised about identity and purity oftest compounds in some studies;
no revision is recommended.
2,3,3',4,4',5'-HexaCB No new relevant in vivo data available; no revision is recommended. 0.0005 0.0005
(157)
2,3',4,4',5,5'-HexaCB No new data are available; no revision is recommended. 0.00001 0.00001
(167)
2,3,3',4,4',5,5'-HeptaCB (189) New data for immunotoxicity (91) are within the range ofthe current value; no revision is recommended. 0.0001 0.0001
Di-ortho PCBs The limited data set as recognized in 1993 still exists. In vivo subchronic assay results with relevant
end points, including CYP1A1/A2 induction and reproductive toxicity, with the structurally similar congener
PCB 153 (98,104,110-112) do not confirm the weak Ah receptor agonist properties reported from in vitro
experiments (11,113,114); as a result, the previous TEF values for di-ortho PCBs have been withdrawn.
2,2',3,3'4,4',5 HeptaCB Withdrawn. 0.0001 -
(170)
2,2',3,4,4',5,5'-OCB (180) Withdrawn. 0.00001 -
Abbreviations: WHO, World Health Organization; CDD, chlorinated dibenzodioxin; CDF, chlorinated dibenzofurans; CB, chlorinated biphenyls, LDSO, median lethal dose; REPs, relative
potencies; OSAR, quantitative structure-activity relationship; EROD, ethoxyresorufin-O-deethylase; Ah, aryl hydrocarbon; PCBs, polychlorinated biphenyls.
alnternational union of Pure and AppliedChemistry numbers are shown in parentheses.
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end points (70-72). Birds, in contrast with cytes indicate that some di-ortho PCBs, e.g., which could confirm anAh receptor-mediated
fish, show a more pronounced response to PCBs 128, 138, 170, and 180, arealso EROD responsebythesecongeners.
mono-ortho PCBs, and REPs resemble those inducers (69,73,74). However, in ovo studies When REPs for CYPlAI induction and
found in mammalian systems. In addition, with either biochemical or toxic end points embryo mortality in avian systems are com-
studies with cultured chicken embyo hepato- have not been done with these di-ortho PCBs, pared, it can beconcluded that nosignificant
Table2.Toxic equivalencyfactors (TEFs)forfish
Congener Description WHO TEF
Dioxins
1,2,3,7,8-PentaCDD
1,2,3,4,7,8-HexaCDD
1,2,3,6,7,8-HexaCDD
1,2,3,7,8,9-HexaCDD
1,2,3,4,6,7,8-HeptaCDD
OctaCDD
Furans
2,3,7,8-TetraCDF
1,2,3,7,8-PentaCDF
2,3,4,7,8-PentaCDF
1,2,3,4,7,8-HexaCDF
1,2,3,6,7,8-HexaCDF
1,2,3,7,8,9-HexaCDF
2,3,4,6,7,8-HexaCDF
1,2,3,4,6,7,8-HepaCDF
1,2,3,4,7,8,9-HeptaCDF
OctaCDF
Non-ortho PCBs
3,4,4,5-TetraCB (81)b
3,3',4,4'-TetraCB (77)
3,3',4,4',5-PentaCB (126)
3,3',4,4',5,5'-HexaCB (169)
Mono-ortho PCBs
2,3,3',4,4-PentaCB (105)
2,3,4,4',5-PentaCB (114)
2,3',4,4',5-PentaCB (118)
2',3,4,4',5-PentaCB (123)
2,3,3',4,4',5-HexaCB (156)
2,3,3',4,4',5-HexaCB (157)
2,3',4,4',5,5'-HexaCB (167)
2,3,3',4,4',5,5'-HeptaCB (189)
In a rainbow trout egg injection study, this compound was found to be 0.7 times as potent as 2,3,7,8-TCDD
at causing early life stage mortality (40); a value of 1.0 is recommended.
In a rainbow trout egg injection study, this compound was found to be 0.3 times as potent as 2,3,7,8-TCDD
at causing early life stage mortality (40); a value of 0.5 is recommended.
In a rainbow trout egg injection study, this compound was found to be 0.02 times as potent as 2,3,7,8-TCDD
at causing early life stage mortality (42); a value of 0.01 is recommended.
No in vivostudies have been carried outwith this compound. It was determined to be 0.02 times as
potent as 2,3,7,8-TCDD at inducing EROD in PLHC-1 cells (115); a value of 0.01 is recommended.
In a rainbow trout egg injection study, this compound was found to be 0.002times as potent as 2,3,7,8-TCDD at causing
early life stage mortality (42); a value of 0.001 is recommended.
A two week study in carp using a single ip dose ofthis compound failed to detect any dose or hepatic concentration
relationship with CYP1A induction (5. Based on structure homology with OCDF, a value <0.0001 is recommended."
In a rainbow trout egg injection study, this compound was found to be 0.03 times as potent as 2,3,7,8-TCDD at causing
early life stage mortality (40); a value of 0.05 is recommended.
In a rainbow trout egg injection study, this compound was found to be 0.03 times as potent as 2,3,7,8-TCDD at causing
early life stage mortality revision (40); a value of 0.05 is recommended.
In a rainbow trout egg injection studythis compound was found to be 0.3 times as potent as 2,3,7,8-TCDD at causing
early life stage mortality (40); a value of 0.5 is recommended.
In a rainbow trout egg injection study, this compound was found to be 0.2 times as potent as 2,3,7,8-TCDD at causing
early life stage mortality (40); a value of 0.1 is recommended.
At present, available data are only from QSAR studies (93,116). Also based on structural similarity between the
hexaCDF isomers generally observed in experiments, a value of 0.1 is recommended.
Data from EROD induction in PLHC-1 cells and QSAR studies indicate an REP between 0.04 and 0.09(116); a value
of 0.1 is recommended.
Based on the structural similarity ofthis compound with other hexaCDFs and supported by QSAR modeling (93,116);
a value of 0.1 is recommended.
At present, no in vivo or in vitro data are available from fish studies, but based on structure homology with
1,2,3,4,7,8,9-heptaCDF, a value of 0.01 is recommended.
Data from EROD induction in PLHC-1 cells indicate an REP of 0.01 (116); a value of 0.01 is recommended.
A two week study in carp using a single ip dose ofthis compound failed to detect any dose or hepatic
concentration relationship with CYP1A induction (53). In the PLHC-1 cell line, this compound was 0.0008times as potent
as 2,3,7,8-TCDD at inducing EROD activity (115). However, both studies do not accurately reflectthe environmental
in vivo situation in which extreme low solubility and large molecular size limiting transport overthe gill membranes
(117) should reduce the octaCDF potency forfish significantly. Avalue <0.0001 is recommended."
In a rainbowtrout egg injection study,this compound wasfound to be 0.0006times as potent as 2,3,7,8-TCDD atcausing
early life stage mortality (42); a value of0.0005 is recommended.
In a rainbowtrout egg injection study, this compound wasfound to be 0.0002times as potent as 2,3,7,8-TCDD at causing
early life stage mortality (40); a value of0.0001 is recommended.
In a rainbow trout egg injection studythis compound wasfound to be 0.005times as potent as 2,3,7,8-TCDD at causing
early life stage mortality (40); a value of0.005 is recommended.
In a rainbowtrout egg injection study,this compound wasfound to be 0.00004times as potent as2,3,7,8-TCDD at causing
early life stage mortality (42); a value of0.00005 is recommended.
0.5
0.01
0.01
0.001
<0.0001
0.05
0.05
0.5
0.1
0.1
0.1
0.1
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0.01
<0.0001
0.0005
0.0001
0.005
0.00005
In a rainbowtrout egg injection study, this compound did not cause early life stage mortality atthe highest dose <0.000005
administered (40); a value of <0.000005 is recommended.
Avalue of <0.000005 was assigned based onthe similarityofthe structure ofthis compoundwith other mono-orthopentaCBs. <0.000005
In a rainbowtrout egg injection study, this compound did not cause early life stage mortality atthe highest dose <0.000005
administered (40); a value of <0.000005 is recommended.
A value of <0.000005 was assigned based on structural similarity ofthis compound with other mono-ortho pentaCBs. <0.000005
An in vitro studywith the rainbowtrout RTG-2 cell line supportsthe earlier assigned value of <0.000005forthe other <0.000005
mono-ortho PCBs (47). In another in vitrostudywith the rainbowtrout cell line RTL-2,this compound was 0.00003
times as potent as TCDD in inducing EROD activity(45); a value of <0.000005 is recommended.
A value of <0.000005 was assigned based on structural similarity ofthis compound with other mono-ortho pentaCBs; <0.000005
this value is also supported by QSAR modeling (118).
A value of <0.000005 was assigned based on structural similarity ofthis compound with other mono-ortho pentaCBs. <0.000005
A value of <0.000005 was assigned based on structural similarity of this compound with other mono-ortho pentaCBs. <0.000005
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Abbreviations:WHO,World Health Organization; CDD, chlorinated dibenzodioxins; ip,intraperitoneal; EROD, ethoxyresorufin-O-deethylase; CDF, chlorinated dibenzofurans; QSAR, quan-
titative structure-activity relationship; REP, relative potency; CB, chlorinated biphenyl.
"After a postmeeting consultation in February 1998, we agreed upon a revision ofthe TEFvaluesfor octaCDDand octaCDF infish and birds, which were presented atthe 17th International Symposium on Chlorinated
Dioxins and Related Compounds on25-29August 1997 in Indianapolis, Indiana.
binternational Union of Pure andApplied Chemistry numbers are shown in parentheses.
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differences have been found between these
values. Thus, the relative potencies of these
compounds, as determined by CYPlAI
induction in cultured avian hepatocytes,
appear to be predictive for the relative toxici-
ty in thedevelopingembryo (66).
However, some toxic end points, such
as porphyrin accumulation in cultured
avian hepatocytes, should be approached
with caution because structure-activity
relationships differ significantly from those
of CYPIA induction (74-76). Based on
this information, it is unclear ifporphyrin
accumulation in birds is uniquely an Ah
receptor-mediated effect. Therefore, it is
unclear whether it should be included in
the TEF concept. This case again stresses
the importance to include only those end
points in which the Ah receptor-mediated
mechanism is shown to be involved and is
the major determining factor.
Review of TEFs
Approach for DerivingTEFs
For reevaluation ofthe existing mammalian
TEFs for PCDDs, PCDFs, and PCBs, both
previously reviewed and new data were exam-
ined. These included all congeners that have
been selected before and alsopublished dataof
multiple ortho-substituted PCBs (1,11,77,78).
Forprioritization, arankorderwasfollowed as
was suggested at an earlier WHO/IPCS TEF
meeting (1). TheTEFs forhumans and mam-
malswereprimarilyderivedfrom in vivotoxic-
ity data, which were given more weight than
in vitro and/or quantitative structure-activity
relationship (QSAR) data. In vivotoxicitydata
were prioritized according to the following
ranking scheme: chronic > subchronic > suba-
cute > acute. In the final TEF selection, differ-
ent Ah receptor-specific end points were also
ranked according to toxic> biochemical (e.g.,
enzyme induction) response. For revision of
the existing mammalian TEFs, we agreed that
if the available information was considered
insufficient to warrant a change, the existing
value would remain. The suggested TEFs for
humans and mammals, including a short
description, aregiven inTable 1.
A tiered approach was followed in deriv-
ing TEFs for fish and birds. Following this
approach, we noted that the number ofbird
and fish studies, which could be used for the
derivation ofa TEF, was often very limited
when compared with mammalian data. For
all congeners, the studies that were given the
most weight were tier 1 studies, followed by
tiers 2, 3, and 4. The tiers were as follows:
Tier 1: Overt toxicity observed in devel-
oping embryos; the only end point used
was the LD50
* Tier 2: Biochemical effects observed in
developing embryos; the only end point
used was the relative potency to induce
CYP1A
* Tier 3: Biochemical effects observed in in
vitro systems; the only endpoint used was
the REP to induceCYPIAincultured cells
* Tier 4: Estimates from QSAR studies.
Fish studies that determined early life
stage mortality were considered to be most
useful for determining TEF values (40,42.
In addition, there was a preference to use
results from egg injection studies in which
the dose to the egg was known, rather than
results from waterborne studies in which this
was not determined. Furthermore, TEF val-
ues for octaCDD, octaCDF, and the mono-
orthoPCBs forfishwere given a "lowerthan"
value. This approach was chosen because fish
appear to be very insensitive, if sensitive at
all, toward anAh receptor-mediated response
of octaCDD, octaCDF, or these types of
PCBs. Nevertheless, we recognizedthatsome
regulatory agencies would like to have some
directions for possible TEF values of these
compounds in fish. Therefore, based on the
present state ofthe science, a "smaller than"
TEF value was given for these compounds,
which should be considered to be the expect-
ed upper limit ofsuch a compound in fish.
The suggested TEFs for fish, including a
shortdescription, aregiven inTable 2.
Few studies have been carried out to
determine the overt toxic effects ofPCBs in
bird embryos after injection of compounds
into eggs. Where data from tier 1 studies
were available, they were used to derive
TEFs, but TEF values of PCDDs and
PCDFs for birds were mainly derived from
tier 2, 3, or 4 studies. These data include
mainly studies that measured EROD induc-
tion in cultured hepatocytes or derived
QSAR. The suggested avian TEFs, includ-
ingashort motivation, are given inTable 3.
In line with the already existing TEF
values, new TEFs were rounded to a value
ofeither 1 or 5, irrespective ofthe order of
magnitude difference with the reference
compound, TCDD.
Discussion
Molecular Basis forTEFs across
Species
A strict criterion for application ofthe TEF
concept is that a compound must be demon-
strated to bind to the Ah receptor since most
(if not all) biological effects of these com-
pounds appear to be mediated by the Ah
receptor (128,129). Studies of biological
effects of 2,3,7,8-TCDD and related poly-
halogenated polyaromatic hydrocarbons have
made it apparent that there are extensive and
important species differences in the function-
al responses elicited by these compounds
(130). However, for a number of common
biological effects, many species can respond
at dose levels that are within one order of
magnitude (131).
With regard to the ligand binding proper-
ties ofthe Ah receptor, most data on receptor
interaction with PCDDs, PCDFs, and PCBs
have been generated using rodentexperimental
model systems. In addition, there are data on
the ligandbindingspecificityofthe humanAh
receptor (129,132-134). The mouse has been
studied in most detail with regard to determi-
nants in Ah receptor structure ofligand bind-
ing activity. Four differently sized allelic vari-
antsofthe receptorhavebeendescribed, which
show extended C-terminal parts as well as
point mutations that affect binding of2,3,7,8-
TCDD and other polyhalogenated aromatic
hydrocarbons (135,136).
With regard to humans, theAh receptor
is detected in a wide variety oftissues (e.g.,
placenta, liver, lung) and primary/estab-
lished human-derived cell lines. Moreover,
the Ah receptor can be activated both in
vivo and in vitro into a DNA binding state
by a variety ofhalogenated aromatic hydro-
carbons (134,137,138). As in mice, a simi-
lar situation with several different allelic
variants ofthe receptor might be present in
humans. Although the mean 2,3,7,8-
TCDD binding affinity (Kd) for the human
Ah receptor may be lower than that
observed in responsive mouse strains
(C57BL/6J), there exisits a range ofKd val-
ues similar in magnitude to the range
observed between responsive and nonre-
sponsive mouse strains (135).
The extension of the TEF concept to
other classes ofvertebrates such as fish and
birds is supported by data on ligand binding
properties oftheAh receptor in thesespecies.
In this respect it should be noted that theAh
receptor has been detected in both bony and
cartilagenous fish (139-141). Thus, it
appears that the Ah receptor is phylogeneti-
cally very old, which is supported by the
fact that development of these fish groups
diverged from one another about 450-550
million years ago. Moreover, there exist
homologs ofboth the receptor gene and the
gene encoding the dimerization partner of
the receptor, Arnt, in the nearly entirely
sequenced genome of the nematode worm
Caenorhabditis elegans. Studies using
species-specific recombinant cells and pri-
mary cultures from birds also suggest that
the ligand binding specificity of the Ah
receptor may not be identical between
species (66,142). Furthermore, one study
determined the specific binding characteris-
tics of TCDD to the Ah receptor in four
different avian species and found differences
in binding affinity ofover an order ofmag-
nitude (62'). Consequently, some caution in
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the absolute homology of ligand binding binding properties ofthe Ah receptor, sup- to CYP1A2 leading to hepatic sequestration,
properties of the Ah receptor between port the use oftheTEF concept across taxa. and 3) relative rates of metabolism.
species maybejustified. . . Lipophilicity controls the rate and extent of
In conclusion, theAh receptor andArnt The Role ofPhTracono netinaneTd absorption, tissue distribution, and passive
have beenverywell conserved during evolu- Food Chain Transport in the TEF elimination. In addition, the chlorine substitu-
tion, indicating that they may have impor- Concept tion pattern determines hepatic sequestration
tant physiological functions, possibly in The pharmacokinetic behavior ofdioxinlike and rate of metabolism. Pharmacokinetic
development (27). This evolutionary con- compounds and PCBs is largely governed by properties have been shown to play a role in
servation, in combination with the ligand three major factors: 1) lipophilicity, 2) binding the determination ofTEF values for a number
Table3. Toxic equivalencyfactors (TEFs) for birds
Congener Description WHO TEF
Dioxins
1,2,3,7,8-PentaCDD
1,2,3,4,7,8-HexaCDD
1,2,3,6,7,8-HexaCDD
1,2,3,7,8,9-HexaCDD
1,2,3,4,6,7,8-HeptaCDD
OctaCDD
Furans
2,3,7,8-TetraCDF
1,2,3,7,8-PentaCDF
2,3,4,7,8-PentaCDF
1,2,3,4,7,8-HexaCDF
1,2,3,6,7,8-HexaCDF
1,2,3,7,8,9-HexaCDF
2,3,4,6,7,8-HexaCDF
1,2,3,4,6,7,8-HeptaCDF
1,2,3,4,7,8,9-HeptaCDF
OctaCDF
Non-ortho PCBs
3,3',4,4'-TetraCB (77)
3,4,4',5-TetraCB (81)
3,3',4,4',5-PentaCB (126)
3,3',4,4',5,5'-HexaCB (169)
In a chicken embryo egg injection study, this compound was found to be approximately equipotent to 2,3,7,8-TCDD
as an inducer of EROD (119). In addition, a studywith chick embryo hepatocytes from several bird species
determined thatthe potency ofthis compound to induce EROD is similar or even higher than that ofTCDD
(68,69); a value of 1 is recommended.
In a chicken embryo egg injection study this compound was found to be approximately 0.05 times less potent than
2,3,7,8-TCDD as an inducer of EROD (119); a value of 0.05 is recommended.
In a chicken embryo egg injection study, this compound was found to be approximately 0.01 times less potentthan
2,3,7,8-TCDD as an inducer of EROD (119); a value of 0.01 is recommended.
Intwo chicken embryo egg injection studies, this compound wasfound to be approximately 0.1-0.4 times less potent
than 2,3,7,8-TCDD as an inducer of EROD (119,120); a value of0.1 is recommended.
In a chicken embryo egg injection study, this compound was found to be a poor inducer of EROD (119); a lower
than value of0.001 is recommended.
At present, no in vivoor in vitrodata are available forthis compound in birds; a value of0.0001 was recommended
based on data from mammalian studies.a
Chicken embryo egg injection studies and one studywith chicken embryo hepatocytes of several species of birds
found this compound to be approximately equipotent or even more potentthan 2,3,7,8-TCDD as an inducer of
EROD (66,119,121); a value of 1 is recommended.
In a chicken embryo egg injection study, this compound was found to be approximately 0.3 times less potentthan
2,3,7,8-TCDD as an inducer of EROD (119); a value of0.1 is recommended.
Studies with chicken embryo egg injections and chick embryo hepatocytes from several bird species indicated that
this compound is approximately equipotentto 2,3,7,8-TCDD as an inducer of EROD (68,119); a value of 1.0 is
recommended.
This compound was reported to be 0.01 times as potent as 2,3,7,8-TCDD as an inducer of EROD in chicken embryos
after egg injection (119). However, examination ofthe dose-response curves indicates problems with rigorous
comparison tothatof2,3,7,8-TCDD. Based on QSAR calculations with other existing bird data (M. Tysklind and
P.L. Anderson, University of Umea, Sweden), a value of0.1 is recommended.
In a chicken embryo egg injection study, this compound wasfound to be approximately 0.4 times less potentthan
2,3,7,8-TCDD as an inducer of EROD (119). In combination with QSAR calculations with other existing bird data
(M.Tysklind and P.L. Anderson, University ofUmea, Sweden), a value of0.1 is recommended.
No in vivoor in vitrodata are available. Based on GSAR calculations with other existing bird data (M. Tysklind and
P.L. Anderson, University of Umea, Sweden), a value of0.1 is recommended.
No in vivo or in vitrodata are available. Based on QSAR calculations with other existing bird data (M. Tysklind and
P.L. Anderson, University of Umea, Sweden); a value of0.1 is recommended.
Atpresentno data are available forthis compound in birds; a value of 0.01 is recommended based on similar
homolog class REPs across taxa forthe hexaCDFs and heptaCDFs.
At present, no data are available forthis compound in birds; a value of0.01 is recommended based on similar homolog
class REPs across taxa forthe hexaCDFs and heptaCDFs.
At present, no in viva or in vitro data are available forthis compound in birds; a value of 0.0001 was recommended
based on data from mammalian studies.a
Studies with chickens and wild avian species reported in vitro and in ovoeffects, with REPs ranging from <0.0003
to 0.15 depending onthe species (66,68,69,122,123). Avalue of0.05 is recommended.
Egg injection studies have not been carried out with this compound. Two studies with chick embryo hepatocytes
from several bird species indicate a wide range of REPs (0.001- 0.5) ofthis compound to induce EROD relative
to TCDD (66,68). Asfor most species, REPs were close to a value of0.1, which isthe recommended value.
A24-hr studywith chickens determined a REP of0.07 (124); a value of0.1 is recommended.
One study determined the LD50 in chicken embryos after injection ofthe compound intothe egg, and a REP of0.002
was reported (125,126). Avalue of0.001 is recommended.
continued, nextpage
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of dioxinlike chemicals. These factors can
indude alterations in absorption, tissue distrib-
ution, and metabolism between individual
congeners.
The importance of pharmacokinetic
factors has been illustrated with studies
using octaCDD in rodents. This com-
pound initiated dioxinlike responses follow-
ing subchronic exposure to rats, with an
estimated relative potency of0.01 based on
hepatic levels correlated with the induction
of CYPlAI (87). However, earlier acute
toxicity studies had suggested that
octaCDD was essentially nontoxic, with a
TEF value less than 0.000001. These sub-
chronic studies also showed that octaCDD
is extremely poorly absorbed and absorp-
tion from the gastro-intestinal tract
decreased with increasing dose (143).
Consequently, very little is stored from a
(single) high dose ofoctaCDD in tissues of
animals. In contrast, repeated exposure to
relatively low doses can lead to significant
tissue accumulation and hence a biological
response. Based on these findings, it can be
discussed whether future TEF values should
be based on intake or tissue level values to
bridge differences between species.
Differences in tissue distribution can also
significantly influence TEF values based on
tissue concentrations. The liver/adipose tissue
distribution can vary significantly between
the species and dose levels used (95). A num-
ber of highly toxic congeners such as
2,3,4,7,8-pentaCDF, 2,3,7,8-TCDD, and
PCB 126 bind very tightly to CYP1A2 and
subsequently concentrate in the liver in many
rodent species, even at very low dose levels
(88,131,144-148). In this respect, it should
be noted that the structure-activity relation-
ship for binding to the Ah receptor and to
CYP1A2 are not identical (149). As the level
of CYP1A2 is increased, dioxinlike com-
pounds redistribute from the adipose tissue
back to the liver. Thus, depending on the
species and dose level, the binding ofan Ah
receptor agonist to CYP1A2 can alter tissue
distribution. As a result of this CYP1A2
binding, hepatic REPs for these compounds
are lower than those based on intake because
of disproportionately high liver concentra-
tions. However, if other tissues are consid-
ered, e.g., skin and lung, the REP values
would be higher because the tissue concentra-
tions are lower than expected based on
administered dose (81).
The distribution of PCBs in laboratory
animals differs significantly from that ofthe
2,3,7,8-substituted PCDFs and PCDDswith
respect to liver distribution. Highlybiopersis-
tent PCBs, e.g, PCB 153, are predominantly
stored in adipose tissue and skin and not in
the liver (150). Nevertheless, PCB congeners
that are isostereomers ofTCDD, such as
PCB 126, attain a high liver concentration.
With the addition ofone ortho chlorine, the
hepatic accumulation decreases dramatically,
as was shown in comparative semichronic
studies with rats and PCBs 126 and 156
(103,109). These differences again appear to
be related to induction of and binding to
CYP1A2. It has also been shown that co-
administration of PCDDs, PCDFs, or
dioxinlike PCBs with the nondioxinlike con-
gener PCB 153 can result in modulation of
the hepatic disposition and elimination
(151-153). These toxicokinetic interactions
are quantitatively limited, compound and
dose dependent, and probably the result of
multiple mechanisms involving, among oth-
ers, de novosynthesis ofboth theAh receptor
and CYP1A2 (151). To some extent, these
toxicokinetic interactions could explain the
nonadditive effects that were observed when
combinations ofdioxins and PCB 153 were
used in rodent studies (95). To what extent
these toxicokinetic interactions are also rele-
vant at low-level environmental exposure is
still unknown.
The position and degree of halogena-
tion determines the rate and extent of
metabolism, which is the key determinant
of excretion or bioaccumulation of these
compounds (95,154). Full lateral halogena-
tion at the 2,3,7,8-positions produces
PCDDs and PCDFs that lack two adjacent
unsubstituted carbon atoms. These con-
geners tend to be very resistant to metabo-
lism, as these positions are also preferential-
ly oxidized by the cytochrome P450 sys-
tem, most likely by the CYPIA enzymes.
Because of the stress on the furan ring,
PCDFs are more susceptible to biochemi-
cal degradation than PCDDs. In addition,
the positions adjacent to the oxygen bridge
in the PCDF molecule (positions 4 and 6)
are more sensitive to metabolic attack than
those in the PCDD molecule (95).
For PCBs the presence oftwo adjacent
unsubstituted carbon atoms also facilitates
the metabolic conversion to more polar
metabolites. As with PCDFs and PCDDs,
the cytochrome P450 IA enzyme(s) seems
to play an important role in metabolism of
Table3.(continued)
Congener Description WHO TEF
Mono-ortho PCBs
2,3,3',4,4'-PentaCB (105) One study determined the LD50 in chicken embryos after injection ofthe compound intothe egg, and a REP value of 0.0001
0.00014 was reported (125,126). Avalue of0.0001 is recommended.
2,3,4,4',5-PentaCB (114) At present, available data are onlyfrom QSAR studies(74,102,127); based on these calculations, a value of0.0001 0.0001
is recommended.
2,3',4,4',5-PentaCB (118) One studywas carried outto determine the LD in chicken embryos afterinjection ofthe compound into the egg; 0.00001
atthe highestdoses, no lethality wasobserved]126). This compound is also a poor inducer of EROD in avian
hepatocyte cultures (66); a value of0.00001 is recommended.
2',3,4,4',5-PentaCB (123) At present, available data are onlyfrom QSAR studies (74,102); based on these calculations, a value of0.00001 is 0.00001
recommended.
2,3,3',4,4',5-HexaCB (156) One study determined the LD50 in chicken embryos afterinjection ofthe compound intothe egg and reported a REP 0.0001
of0.0002(126). Avalue of0.0001 is recommended.
2,3,3',4,4',5'-HexaCB (157) One study determined the LD50 in chicken embryos after injection ofthe compound intothe egg, and reported a REP 0.0001
of0.0001 (126). A value of0.0001 is recommended.
2,3',4,4',5,5'-HexaCB (167) One study determined the LD50 in chicken embryos after egg injection and reported a REP <0.00008(126). A value 0.00001
of0.00001 is recommended.
2,3,3',4,4',5,5'-HeptaCB (189) No in vivo or in vitrodata are available. Based on QSAR calculations with otherexisting bird data (M.Tysklind 0.00001
and P.L. Anderson, University of Umea, Sweden), a value of0.00001 is recommended.
Abbreviations: WHO, World Health Organization; CDD, chlorinated dibenzodioxins; EROD, ethoxyresorufin-O-deethylse; CDF, chlorinated dibenzofurans; QSAR, quantitative
structure-activity relationship; REPs, relative potencies; CB, chlorinated biphenyl, LD50, median lethal dose.
aAfter a postmeeting consultation in February 1998, we agreed upon a revision ofthe TEFvalues for octaCDD and octaCDF in fish and birds, which were presented atthe 17th International Symposium on Chlorinated
Dioxins and Related Compounds on 25-29August 1997 in Indianapolis, Indiana.
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those PCB congeners that are more or less
isosteric with 2,3,7,8-TCDD (155). This is
based on a study with rats, marine mam-
mals, and wild bird species in which it was
observed that the metabolic degradation of
PCB 77 correlated well with EROD activi-
ty. However, the same study indicated that
for fish species this isoenzyme might be less
effective in metabolizing these PCBs (156).
In addition, several other P450 isoenzymes,
e.g., P450 2B and 3A, might be involved in
the metabolism of PCBs that have an
ortho-substitution pattern. With an increas-
ing ortho chlorine substitution pattern, the
induction of P450 2B1 and 2B2 isoen-
zymes increases significantly (155,157).
Studies with PCB patterns and enzyme
activities in wild mammals indicate that, at
least in seals and polar bears, the involve-
ment ofCYP2B isoenzymes in metabolism
ofPCBs cannot be excluded (158,15-9).
The role ofmetabolism can also be impor-
tant when comparing acute and subchronic
studies. In rodent studies using both 2,3,7,8-
TCDF and TCDD, it was demonstrated that
the REP of2,3,7,8-TCDF for enzyme induc-
tion was almost equal to that ofTCDD after
acute exposure. However, when subchronic
studies were done, 2,3,7,8-TCDF was much
less potent than TCDD due to its rapid
metabolism and lack ofbioaccumulation (88).
A similar explanation was suggested when
comparing the relative potencies for the induc-
tion of cleft palate in mice by 1,2,3,7,8-
pentaCDF versus 2,3,4,7,8-pentaCDF (160).
When comparing the brominated dioxins and
dibenzofurans with the chorinated ones, it
appears that at least some brominated com-
pounds can be more resistant to metabolism
than their corresponding chlorinated analogs
(12). Species differences in metabolism might
also be one ofthe causes for the observed dif-
ferential TEFs between fish, birds, and labora-
tory mammals. For example, some fish and
birds may have limited ability to metabolize
PCB 77 and 2,3,7,8-TCDF. However, both
lay eggs and embryos have little depuration
capability compared to adults. The respective
avian and mammalian PCB 77 and 2,3,7,8-
TCDFTEFsdemonstrate morepotency in ovo
than in vivo. The PCB 77 and 2,3,7,8-TCDF
TEFs are higher in bird eggs/embryos without
a postconception maternal influence than in
mammalian embryos with matemal metabolic
protection. Conversely, a similar fish and
mammalian comparison shows almost identi-
cal fish egg/embryo and mammalian TEFs.
The role ofmetabolism, subsequent elimina-
tion, and reproductive strategy differences,
especially through maternal egg deposition for
most nonmammalianvertebrate species, points
to the need to focus future REP/TEF determi-
nations on in vivoor in ovostudies with com-
parisons between target organ or tissue
exposure measurements and toxicity end
points. In addition, it points to the need to
base future TEF values on in vivo studies in
which steady-state conditions are obtained or
at least have been approached. Utilizing this
approachwill greatlyincreasethevalueoflabo-
ratory-determined exposure measurements for
data interpretation in similar environmental
samples regardless oftaxonomicgroup.
As illustrated above, many PCBs,
PCDFs, and PCDDs are relatively resistant
to metabolism and can therefore accumu-
late in different trophic levels, causing bio-
magnification and toxicity higher in the
foodchain (161). For PCDDs and PCDFs,
the structure-activity relationships for
bioaccumulation are relatively simple and
involve primarily the 2,3,7,8-substituted
congeners for most vertebrate species. Only
in some invertebrates and the guinea pig
has the accumulation ofnon-2,3,7,8-substi-
tuted PCDDs and PCDFs been found to
be significant, but the guinea pig has been
found to have low metabolic capacities for
these compounds (95). Thus, from a phar-
macokinetic point ofview, onlythe 2,3,7,8-
substituted congeners should be considered
when TEFs must be determined for ecotox-
icological riskassessment ofvertebrates.
For PCBs the situation is more com-
plex, as structure-activity relationships are
less well defined for metabolism and associ-
ated bioaccumulation. The degree ofaccu-
mulation is strongly determined by the
capability of the organism to metabolize
the various PCB congeners (22,162). This
can differ qualitatively as well as quantita-
tively between species. In general, it can be
stated that fish are less capable ofmetabo-
lizing PCBs than most birds and mammals.
In spite of the complexity of the above
processes, the lack ofchlorine substitution
on both the meta andpara positions in the
PCB molecule appears to facilitate the
metabolism of these compounds in most
higher vertebrate species (21,156,158,163).
As a result ofthis "biofiltering" by metabo-
lism at different levels in the foodchain, the
qualitative PCB pattern in top predators
shows some resemblance, which allows
selection of PCB congeners of major con-
cern for risk assessment (164).
Qualitative and quantitative changes
occur in PCDD, PCDF, and PCB patterns
among different trophic levels and between
the abiotic and biotic components ofdiffer-
ent ecosystems. This is especiallyconfounded
when attempts are made to perform risk and
exposure assessments from a contaminated
soil or sediment. It is preferable and indeed
desirable to model Ah receptor-active con-
geners from abiotic to biotic components of
ecosystems because ofdifferential partitioning
across these matrices, which areinfluencedby
physicochemical properties, physiological dif-
ferences, food chain position, and different
reproductivestrategies.
Depending on the assessment and toxic-
ity end points identified in a particular eco-
logical risk assessment, application of the
appropriate TEFs for fish, birds, or mam-
mals, as well as resultingTEQs, should only
be determined in biotic matrices after the
quantitative estimates of congener concen-
trations are made in a particular target
species or generic food chains. Conversely,
TEQs in abiotic matrices could be misused
and have obscurevalue. For example, calcu-
lating TEQs in sediment or soil does not
harm or place any risk on these abiotic
matrices, regardless of TEF scheme. The
apprlication of the TEF concept for food-
chain transport out ofthe abiotic compart-
ments is clearlyan areafor future research.
Application ofin VitroAssays in the
Derivation ofTEFs
A number of in vitro assays, either in pri-
mary cultures or immortalized cells, have
been used to establish REPs for mammals,
birds, and fish. These indude assays for Ah
receptor competitive ligand binding,
CYPlAl gene induction, cell differentia-
tion, plaque-forming cell (PFC) response,
and porphyrin accumulation.
The most extensively used biological in
vitroresponse studied so far is the induction
ofthe CYPIAJ gene. CYPJAJ gene induc-
tion has been measured by monitoring
changes in mRNA (165,166), protein levels
(66,167), and/or enzyme activity [i.e.,
EROD or aryl hydrocarbon hydroxylase
(AHH)] (168,169).
In addition, permanently transfected
cells have also been established that contain
CYPlA-regulated reporter genes. These cell
lines contain a permanently incorporated
reporter gene that is regulated by the
mouse CYPlAl regulatory region (55,142,
170,171). These cell lines have a number
of advantages over conventional enzyme
induction assays such as 1) a sensitive and
more easily measurable enzyme activity; 2)
chemical inducers do not act as competitive
inhibitors of the reporter gene; and 3) a
larger number ofavailable species- and tis-
sue-specificassays.
Only two studies have compared
endogenous EROD induction to reporter
gene induction (55,172). The structure-
activity relationship ofthe tested chemicals
was comparable between wild-type and
recombinant H4IIE cells. Dose-response
relationships exhibited comparable dynamic
ranges, and binary mixtures ofTCDD, PCB
126, and PCB 77 did not depart from addi-
tivity in either cell line. In addition, PCB
153 significantly antagonized induction by
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TCDD and PCB 126 in both cell lines. The
recombinant cell line was found to be gener-
ally more sensitive to PCDDs, PCDFs, and
PCBs when compared to the wild-type cells
(172). Additionally, Richter et al. (55)
recently reported that a recombinant trout
cell line (RLT 2.0) could be used as an
approximate predictor of responses in fish.
However, the use ofthis assaywas not advo-
cated to develop REPs for ecological risk
assessment since it was still plagued by the
samedrawbacks thatlimit the utilityofother
in vitroassays.
In vitro CYP1A induction has also been
used to assess the level ofdioxin equivalents
(TEQs) in a number ofenvironmental sam-
ples (69,173-177). Ingeneral, theTEF/TEQ
approach using CYP1A induction accurately
predicted dioxin equivalents within a com-
plex mixture when compared to gas chro-
matography-mass spectrometry analysis or in
vivo assessments, but may overestimate the
TEQs when using other responses such as
PFC (91). The accuracy of this in vitro
approach also depends on the composition of
the sample. The presence ofhigh amounts of
Ah receptor agonists that are not covered by
the TEF concept (e.g, polycyclic aromatic
hydrocarbons) can result in a considerable
overestimation ofTEQs in environmental
samples. Furthermore, these in vitro studies
have shown that some responses (i.e., PFC,
reporter gene, and AHH/EROD induction)
and cell lines (H4ILE, recombinant reporter
cells) are susceptible to nonadditive interac-
tions. This is especially true ifthe complex
mixture contains PCB congeners thatarepar-
tialAhreceptoragonists(91,142,178,179).
In summary, a single in vitro assay
based on a single surrogate species may not
accuratelypredict the toxicity ofa chemical
or complex mixture following exposure to
other species. Nevertheless, the use of in
vitro assays provides a general tool as a pre-
screening method ofTEQs in environmen-
tal samples. However, it does not replace in
vivo experiments when determining TEFs
for dioxinlikecompounds.
The Use ofQSARs for Identification
andScreeningofDioxinlike
Compounds
PCDDs, PCDFs, and PCBs consist ofa large
number ofpossible congeners with varying
degrees ofchlorination and substitution pat-
terns. Thus, from a practical point ofview, it
does not seem feasible to test extensive num-
bers ofcongeners for their biological or toxic
properties. Thedetermination ofQSARscould
facilitate future risk assessment procedures sig-
nificantly. Based on a limited number ofcom-
pounds, structure-activity relationships have
been developed for Ah receptor-mediated
effects, e.g., induction ofCYPlAl andbinding
to this protein (11,129,180). In addition,
structure-activity relationships have also been
determined for effects that are not directly
related to the Ah receptor and involve both
parent compounds and their hydroxylated
metabolites. These non-Ah receptor-mediated
structure-activity relationships indude binding
to transthyretin and thyroxin-binding globulin
(6j181,182), binding to the estrogen receptor
(183,184), and decrease in dopamine levels
(2,3). Basedon these studies itcan be conclud-
ed that the structure-activity relationships of
the latter effects deviate significantly from
those observed for the Ah receptor-mediated
effects. As only Ah receptor-mediated effects
are considered in the present TEF concept,
these structure-activity relationships will not
further be considered in this evaluation (see
criteriaabove).
Mostbiological systems arecomplex, and
it is unlikely that only one or a few chemical
properties will suffice to describe them.
Thus, it is necessary to characterize these
compounds with a multitude of physico-
chemical descriptors. Such a broad chemical
characterization may capture the underlying,
hidden factors that correlate with the
response of interest. This information can
then be used as the future base for the selec-
tionofcongeners forbiological testing (185).
Within the TEF concept, the critical
question is howtoidentify thephysicochem-
ical properties that determine ifa compound
can be expected to be dioxinlike or not. The
planar structure of the PCDDs and the
PCDFs is characteristic for high Ah receptor
binding affinity. Furthermore, the 2,3,7,8-
chlorine substitution pattern is of great
importance as well. PCBs show a larger
chemical variation due to the possible rota-
tion ofthe two phenyl rings. The number of
chlorine atoms in the ortho-position will, in
this case, define the degree of dioxinlike
properties. However, from a chemical point
ofview, it is difficult to define the point at
which the compounds lose their dioxinlike
properties. As a consequence ofthis, no sin-
gle PCB congener can be identified as being
structurally representative for the whole dass
ofcompounds. Hence, a number of con-
geners must be investigated in order to
indude the manyfacets ofchemical structure
within the PCB class ofchemicals.
The use ofmultivariate chemical charac-
terization (118) in combination with factorial
design provides a tool by which small sets of
structurally representative congeners can be
selected. This tool can be used in the design
ofin vitroand in vivoexperiments in order to
introduce systematic structural variation in
the congeners to be tested. In studies ofcom-
plex environmental mixtures, indicator con-
geners can be selected from the structural
variation found in such matrices as flue gases
from incineration plants orAroclor mixtures.
The use ofthese systematic and balanced sets
of congeners in the experimental protocol
will provide increased knowledge ofthe bio-
logical behaviorofthecompounds studied.
Small sets ofcongeners, representative for
the PCDDs, PCDFs, and PCBs, have been
suggested (186,187). Twenty congeners were
selected based only on their physicochemical
properties and not on expected biological
activity. As a first screening ofpossible dioxin-
like effects, PCDFs and PCBs were tested in
different in vitro systems using primary hepa-
tocytes from differentspecies aswell as rat and
fishhepatomacelllines. Basedon theseresults,
QSARs have been established to define the
correlation between chemical properties and a
dioxinlike biochemical response. As can be
seen in Table 4, these studies predict that a
large number of PCBs, and also PCDFs,
exhibit dioxinlike activity measured as in vitro
inductionofCYPIA(1) activity.
The systematic selection approach makes
itpossible to make interpolations andpredic-
tions ofnotyet tested congeners. In thisway,
all congeners within the chemical range in
which the selection of test congeners were
made can be ranked according to expected
dioxinlike activity and the congeners ofspe-
cial interest can be identified and investigat-
ed further. This method has so far mainly
focused on CYPlAI induction, but could
also be used in the screening ofother dioxin-
linked effects or other groups ofhalogenated
aromatics, e.g., polychlorinated naphthalenes
andpolybrominated diphenylethers.
Based on the information presented in
Table4 about thepredicteddioxinlikeactivity
ofPCBs, it should be noted that experimen-
tal data were used from in vitro experiments.
Therefore, the structure-activity relation-
ships determinedwith this multivariate char-
acterization await further confirmation from
in vivo experiments, including the role of
pharmacokinetics, before these dioxinlike
PCBs can be included in the TEF concept.
Nevertheless these QSAR data indicate that
more PCBs might be considered in the
future for inclusion in the TEF concept. In
relation to the large number ofPCDFs that
are predicted to induce CYPIA 1 in vitro
activity, it should be noted that in in vivosit-
uations only the 2,3,7,8-substituted PCDFs
exhibit a significant tissue retention. In this
case, a pharmacokinetic factor (metabolism)
seems to dominate the toxicodynamic aspects
of these non-2,3,7,8-PCDFs (in vitro Ah
receptorbindingandCYPlAI induction).
Uncertainties Associatedwith the
TEF Concept
Toxic equivalency factors were initially
developed for calculating the TEQs in mix-
tures of PCDDs and PCDFs. The TEF
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approach for hazard assessment ofreconsti-
tuted PCDD/PCDF mixtures has been val-
idated using standardized TEF or response-
specific TEF values. In a limited number of
validation studies using mixtures, a good
correlation was found between the observed
in vivo or in vitro response and TEQvalues
calculated from the relative concentrations
of individual congeners in the mixture
(84,188-190). The non-ortho and mono-
ortho PCBs also elicit Ah receptor-mediated
responses. As a consequence, TEFs have
been assigned to these PCBs (1,11,77).
From a risk assessment point of view this
was a logical decision, as most environmen-
tal matrices contain PCDDs, PCDFs, and
PCBs. In fact, in some environmental sam-
ples, the overall contributions of PCBs to
TEQs exceed that of the PCDDs and
PCDFs (191). When concentrations of
TEQs in complex mixtures from environ-
mental matrices were determined in vitro
and compared to TEQs by using REPs
from the same in vitro system, the results
were generallywithin afactor of2 (192).
However, the inclusion of PCBs in the
TEF concept also poses aproblem due to the
nonadditive effects, which have been
observed in laboratory studies with mixtures
containing PCDDs, PCDFs, and PCBs. Ah
receptor antagonist activities ofcertain PCB
congeners, induding the major environmen-
tal contaminant PCB 153, have been report-
ed in several experimental systems. Recendy,
these nonadditive interactions of PCB on
dioxinlike effects have been reviewed (193).
In summary, the following antagonistic
effects ofnondioxinlike PCBs were described:
induction ofEROD activity in chick embryo
hepatocytes (194), splenic PFC response to
sheep erythrocytes in mice (195), splenic
PFC response to trinitrophenyl-lipopolysac-
charide in mice (196), serum IgM units in
mice (91), mouse fetal deft palate (110,195),
and chick embryo malformations and edema
and liver lesions (197). The apparent antago-
nism by PCB 153 of the TCDD-induced
immunosupression is due to the enhanced
immune response induced by PCB 153
(198). In addition, synergistic interactions
have also been reported between PCBs and
dioxins in the development ofporphyria in
rats (199) and mice (89), the induction of
CYPIAI (152,178) and thyroid hormone
levels and associated enzyme activities
(200,201). These multiple nonadditive inter-
actions between dioxinlike and nondioxinlike
HAHs require further investigation to estab-
lish the extent to which they compromise the
TEF concept.
Several reports have also questioned the
relative contributions ofTEQsassociatedwith
dioxinlike compounds versus the substantial
daily intakes of natural nonchlorinated
Table 4. Screening of compounds with a relative potency (REP) for PCDFs of at least 10-3 TCDD and for
PCBs of 10-5 of PCB 126 in different in vitrosystems
Compounds and assay Number ofdioxinlike congeners Reference
PCDFs in H411E rat hepatoma bioassay 40 out of87 tetra-through octaCDFs (93)
PCDFs in PLHC-1 fish hepatoma bioassay 47 outof87tetra-through octaCDFs (127)
PCBs in primary hepatocytes from chicken 56 out of 154tetra- through heptaCBs (102)
PCBs in primary hepatocytes from monkey 79 out of 154tetra- through hepta CBs (102)
PCBs in primary hepatocytes from pig 101 out of 154tetra-through heptaCBs (102)
Abbreviations: PCDFs, chlorinated dibenzofurans; PCBs, chlorinated biphenyls. Congeners tested and creating the quan-
titative structure-activity relationship models were selected based on multivariate chemical characterization in combi-
nation with experimental design.
Ah receptor agonists in cooked foods and
vegetables (193,202,203). The Ah receptor
agonist and antagonist activities ofindole-3-
carbinol have been reported (204-206).
Perinatal exposure ofpregnant rats to indole-
3-carbinol resulted in reproductive abnormal-
ities in male rat offspring, which were also
elicited by TCDD in the same study.
However, when comparing the effects caused
by indole-3-carbinol or TCDD, both similar
and different responses were observed (205).
In contrast, a recent study with TCDD or
indole-3-carbizole in rats did not find charac-
teristic TCDD-like responses, e.g., hypopha-
gia, bodyweightloss, and CYPlAI induction
(207). These results suggest that at least in
some animal and cell models, the potential
effects of the natural Ah receptor agonists
could be significant. However, it has been
suggested that the difference in pharmacoki-
netics between natural and halogenated Ah
receptor agonists may decrease the potential
impact ofthe natural agonists in in vivositua-
tions. These possible differences between
halogenated and naturalAh receptor agonists,
such as indole-3-carbinol, in pharmacokinet-
ics and toxicodynamics should be examined
in moredetail in in vivoexperiments.
In view ofthe nonadditive effects men-
tioned above, a question has been raised as to
which effect would compromise the TEF
concept more: antagonism or synergism.
From the available experimental data, it
appears that antagonism is the most com-
monly reported nonadditive effect between
individual dioxinlike compounds and com-
plex mixtures (195,208-212). However, it
should be noted that the occurrence ofeither
antagonism or synergism is ratio and dose
dependent. With respect to nonadditive
effects between TCDD and PCB 153 on
CYPlAI induction in rodents, it was
observedthatsynergism prevailedatthelower
dose levels, while antagonism dominated at
higher dose levels (95). Mechanistically, this
antagonism can be explained by the fact that
less potent congeners still have Ah receptor
binding affinities and therefore are effective
competitors for binding the site (195,209).
This reduces theprobability ofthe more toxic
dioxinlike compounds to bind to the Ah
receptor. However, the less active congeners
do notbindwithsuchahighaffinitythatthey
would effectively induce EROD activity or
cause other Ah receptor-mediated adverse
effects (11). In this respect, some results of
interactive studies with these compounds are
equivocal. Forinstance, 3,3',4,4'-tetraCB and
TCDD caused greater than additive induc-
tion ofAHH activity in the liver ofrainbow
trout at doses calculated to produce 50% or
less ofthe maximum response. However, in
rainbow trout at greater doses, the same mix-
ture was found less than additive (213). In
addition, PCB 153 had an antagonistic effect
on the induction of EROD activity by
TCDD (214), butwasfoundto besynergistic
in anotherstudy(215).
In conclusion, there has been much dis-
cussion about the possible interactions
between and among individual congeners in
complex technical mixtures and extracts of
environmental matrices (216). Based on
receptor theory and the proposed mechanism
ofaction ofAh receptor-active compounds,
an additive model for the prediction of
TCDD TEQs still seems most plausible in
spite ofthealso observednonadditive interac-
tions. It is unlikely that the use ofadditivity
in the TEF concept will result in a great deal
of error in predicting the concentrations of
TEQs dueto synergism orantagonism.
Validation oftheTEF Conceptfor
Environmental RiskAssessments
A range ofvalidation studies with fish and
birds have examined the suitability of an
additive model of toxicity for these com-
pounds. These span from isobolographic
studies ofseveral pairs ofAh receptor ago-
nists (and/or antagonists) to the testing of
complex environmental mixtures found in
the environment.
In rainbowtrout and lake trout embryos,
binary mixtures ofAh receptor agonists were
tested following the isobolographic method
(14,50,217). These interactions on embryo
lethality between congener pairs were, in
general, found to be additive. However, for
the combinations ofTCDD and some non-
ortho PCBs, deviations from additivity that
weredependent on the ratio ofthecongeners
were also reported (49,213,218). With
respect to these nonadditive interactions,
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Table 5.World Health Organization toxic equivalency factors (TEFs) for humans, mammals,fish, and birds
Congener
2,3,7,8-TCDD
1,2,3,7,8-PentaCDD
1,2,3,4,7,8-HexaCDD
1,2,3,6,7,8-HexaCDD
1,2,3,7,8,9-HexaCDD
1,2,3,4,6,7,8-HeptaCDD
OctaCDD
2,3,7,8-TetraCDF
1,2,3,7,8-PentaCDF
2,3,4,7,8-PentaCDF
1,2,3,4,7,8-HexaCDF
1,2,3,6,7,8-HexaCDF
1,2,3,7,8,9-HexaCDF
2,3,4,6,7,8-HexaCDF
1,2,3,4,6,7,8-HeptaCDF
1,2,3,4,7,8,9-HeptaCDF
OctaCDF
3,4,4',5-TetraCB (81)
3,3',4,4'-TetraCB (77)
3,3',4,4',5-PentaCB (126)
3,3',4,4',5,5'-HexaCB (169)
2,3,3',4,4'-PentaCB (105)
2,3,4,4',5-PentaCB (114)
2,3',4,4',5-PentaCB (118)
2',3,4,4'5-PentaCB (123)
2,3,3',4,4',5-HexaCB (156)
2,3,3',4,4',5'-HexaCB (157)
2,3',4,4',5,5'-HexaxCB (167)
2,3,3',4,4',5,5'-HeptaCB (189)
Humans/mammals
0.1a
0.1a
0.1a
0.01
0.0001a
0.1
0.05
0.5
0.1
0.1
0.1a
0.1 a
0.018
0.018
0.00018
0.0001a,cd,e
0.0001
0.1
0.01
0.0001
0.0001
0.0001a,d,f
0.00001a,f
0.0001a,d
TEF
Fisha
0.5
0.01
0.01C
0.001
<0.0001
0.05
0.05
0.5
0.1
0.1d
0.1c,d
0.1de
0.01 c,e
<0.0001C,e
0.0005
0.0001
0.005
0.00005
<0.000005
<0.000005e
<0.000005
<0.000005e
<0.000005
<0.000005d8e
<0.000005e
<0.000005
Birdsa
1b
01b 0.05b
<0.001b
0.0001
1b
0.1b
1b
0.1bd
0.1 d
0.018e
0.018e
0.0001e
0.1 C
0.05
0.1
0.001
0.0001
0.0001g
0.00001
0.000019
0.0001
0.0001
0.000019
0.000019
Abbreviations: CDD, chlorinated dibenzodioxins; CDF, chlorinated denzofurans; CB, chlorinated biphenyls; QSAR, quanti-
tative structure-activity relationship.
'Limited data set.
bin vivoCYP1A induction after in ovoexposure.
C/n vitro CYP1A induction.
dOSAR modeling prediction from CYP1A induction (monkey, pig, chicken, orfish).
'Structural similarity.
ffNo newdata from 1993 review (1).
2QSAR modeling prediction from class specific TEFs.
deviations from strict additivity were less
than a factor of two in the LD50 values
(50,217). In addition, brominated analogs of
2,3,7,8-TCDD and other dioxin, furan, and
biphenyl congeners also showed additive
interactions (14).
When testing synthetic or complex envi-
ronmental mixtures of chemicals in fish,
additivity also appears to be the general case
(219). This was shown with asynthetic mix-
ture ofAh agonists and non-Ah receptor
compounds in rainbow trout early life stage
mortality tests in which results simply fol-
lowed an additive model (40). The additivi-
ty model has also been investigated in fish
through the use ofenvironmentally derived
mixtures. One study used the organic
extract made from lake trout, which was
injected into eggs of hatchery-reared rain-
bow trout (220) and lake trout (221).
Additive toxicity of PCDDs, PCDFs, and
planar PCBs to developing trout embryos
was also evaluated through the direct injec-
tion of environmentally derived mixtures
into newly fertilized eggs (220). The good
agreement between TEQseg calculated with
the trout early life stage mortality TEFs for
concentrations of PCDDs, PCDFs, and
PCBs measured in Lake Michigan lake trout
andTEQsezz measured on the basis oftoxic-
ity ofthe le trout extract to rainbow trout
sac fry following egg injection again suggests
that TEQse are strictly additive and TEFs
for all signiWcant Ah receptor agonists pre-
sentwere included (220).
The results from these studies showed
again that the mixture of these compounds
present in lake trout acted in an additive
fashion when compared with experiments
using single congeners (40). The additive
model oftoxicity is also supported by studies
ofembryotoxicity in birds. The toxicity ofan
environmentally derived mixture of chemi-
cals, induding dioxinlike chemicals, was test-
ed in chicken andfound to beadditive (222).
Additionally, the TEF approach could
also be validated by using TEF factors
derived from experiments in chickens that
were successfully used to predict the embryo
lethality for double crested cormorant eggs
(175,223). The TEF and TEQ approaches
were also succesfully applied in a biological
monitoring studywith great blue herons and
double crested cormorants (224,225). Thus,
as with fish, the additivity in the TEF con-
cept is also supported by studies with (wild)
birds. Based on the use ofmore environmen-
tally relevant species, it can be concluded
that the type of interaction that is most
prevalent among Ah receptor agonists and
non-Ah receptor compounds is additivity.
However, more studies to validate the addi-
tivity in fish and wildlife are required to bet-
ter understand the limitations of the TEF
and TEQapproachs. Yet, evidence from fish
and bird studies indicates that the hazards of
not using such an approach are greater than
the uncertainties currently observed with the
TEF/TEQapproaches.
Conclusions
Based on an extension ofthe existing data-
base (1), TEFs for PCDDs, PCDFs, and
PCBs were reevaluated and either revised
(mammals) or established (fish and birds). A
limited number ofexistingmammalian TEFs
for HAHswere revisedbased on newscientif-
ic information or reevaluation of existing
data. These HAHs included 1,2,3,7,8-
pentaCDD, octaCDD, octaCDF, and PCB
77. In addition, we decided that there was
insufficient in vivo evidence to support Ah
receptor agonist activity and thus determine
TEF values for some di-ortho PCBs.
Therefore, we recommended the withdrawal
ofthe TEF values for PCB 170 and 180 that
wereassignedearlier (seeTable 1) (1).
The mammalian TEFs established by
this WHO expert meeting and presented
here are considered to be applicable for the
human situation as well as for wild mam-
malian species. In addition, TEFs for fish
and birds were determined, which could be
used in ecotoxicological risk assessments of
thesevertebrate classes.
When deriving TEFs for humans/mam-
mals, fish, and birds, we attempted to har-
monize the TEFs across different taxa to the
extent possible, as this would have a clear
advantage from a risk assessment and man-
agement perspective. However, total syn-
chronization of TEFs between mammals,
birds, and fish was not feasible, as there
were obvious indications of orders of a
magnitude difference in TEFs between the
taxa for some compounds. In this respect the
absent or very low response offish to mono-
orthoPCBs compared to mammals and birds
is most noticeable. It is also important to
note that mammalian TEFs are based on
intake (administered dose) while fish and
bird TEFs are based on residue analysis (tis-
sue concentration and administered dose in
egginjectionstudies).
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We also reviewed a number of uncer-
tainties that could compromise the TEF
concept when used for risk assessment pur-
poses. These uncertainties include nonad-
ditive interactions, differences in shape of
the dose-response curve, and species
responsiveness. This was based on the pro-
posed Ah receptor mechanism of action
for PCDDs, PCDFs, and dioxinlike PCBs,
but was also based on a number ofcombi-
nation studies with mammals, birds, and
fish that predicted the measured TEQade-
quately according to t.he dose additive
model-._
Therefore, the prediction of TEQs
according to the TEF model is considered to
be plausible and to be the most feasible
approach for risk assessment ofHAHs with
dioxinlike properties. In view of the avail-
able scientific evidence from studies with
mixtures, it was concluded that it is unlikely
for the use ofthis additive model to result in
a great deal of error in predicting the con-
centrations ofTCDD TEQs or responses at
environmentally relevant levels due to non-
additive interactions.
A summary of the suggested WHO
TEFs for PCDDs, PCDFs, and dioxinlike
PCBs is shown in Table 5.
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